蒙特罗莎治疗 GLUE
$10.57 +$0.32 (+3.12%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $10.57 0.00%
开盘$10.30
昨收$10.25
当日区间$9.88 – $10.67
成交量1.01M
市值$903.21M
市盈率（TTM）–
股息率–
GLUE 相关新闻
匹配 Monte Rosa Therapeutics 或代码 GLUE 的头条新闻，按最新排序。
- Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Cuts Target Price to $28 负面
- Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)
- J.P. Morgan Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Cuts Target Price to $27 负面
- Jefferies Initiates Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Announces Target Price $25
- Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $35
- Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $35 正面
- Wells Fargo Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $29
- Wedbush Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $37
- J.P. Morgan Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $31 正面
- Analysts Are Bullish on Top Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Sagimet Biosciences, Inc. Class A (SGMT) 正面
- H.C. Wainwright Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $25
- Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $28
- Piper Sandler Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $37
- LifeSci Capital Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating
- Insilico Medicine (03696.HK) has nominated the VAV1 molecular glue degrader ISM9546 as a preclinical candidate compound.
暂无评论——快来第一个聊聊 GLUE。